Kinin receptors as targets for cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 3, 2012, Pages 299-312

  Figueroa, Carlos D ^a   Ehrenfeld, Pamela ^a   Bhoola, Kanti D ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Bradykinin; Breast cancer; Cell proliferation; Des Arg 9 bradykinin; Kallikreins; Kinin B 1 receptor; Kinin B 2 receptor; Lung cancer; Matrix metalloproteases; Peptidome; Prostate cancer

Indexed keywords

2,3,4,5,6 PENTAFLUOROCINNAMOYL(2 2,6 DICHLOROBENZYL)TYROSINE N (4 AMINO 2,2,6,6 TETRAMETHYLPIPERIDYL)AMIDE; B 9430; BIOLOGICAL MARKER; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CISPLATIN; CU 201; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; ICATIBANT; KININ; M 1764; M 1846; NAVELBINE; PACLITAXEL; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARCINOMA; CELL PROLIFERATION; CHONDROSARCOMA; CLEAR CELL CARCINOMA; COLORECTAL ADENOMA; DRUG POTENTIATION; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GALLBLADDER CARCINOMA; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; MESOTHELIOMA; NONHUMAN; PROSTATE CANCER; PROTEIN METABOLISM; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KININS; NEOPLASMS; RECEPTORS, BRADYKININ;

EID: 84858250212     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.662957     Document Type: Review

References (117)

1. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res 1991;51:3621-3
2. Taub JS, Guo R, Leeb-Lundberg LM, et al. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63:2037-41 (Pubitemid 36538604)
3. Molina L, Matus CE, Astroza A, et al. Stimulation of the bradykinin B1 receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat 2009;118:499-510
4. Ehrenfeld P, Conejeros I, Pavicic MF, et al. Activation of kinin B1 receptor increases the release of metalloproteases-2 and-9 from both estrogen-sensitive and-insensitive breast cancer cells. Cancer Lett 2011a;301:106-18
5. Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 2003;9:2036-42 (Pubitemid 37139081)
6. Stewart JM. Bradykinin antagonists: discovery and development. Peptides 2004;25:527-32 (Pubitemid 38591560)
7. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nature 2007;7:139-46
8. Bhoola KD, Worthy K, Figueroa CD. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80
9. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77 (Pubitemid 40283969)
10. Bhoola K, Ramsaroop R, Plendl J, et al. Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001;382:77-89
11. Bhoola KD, Misso NL, Naran A, Thompson PJ. Current status of tissue kallikrein inhibitors: importance in cancer. Curr Opin Investig Drugs 2007;8:462-8 (Pubitemid 46868068)
12. Banik RK, Kozaki Y, Sato J, et al. B2 receptor-mediated enhanced bradykinin sensitivy of rat cutaneous C-fiber nociceptors during persistent inflammation. J Neurophysiol 2001;86:2727-35 (Pubitemid 33139043)
13. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. Pain 2000;87:1-5 (Pubitemid 30345656)
14. Calixto JB, Medeiros R, Fernandes ES, et al. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004;143:803-18 (Pubitemid 39664839)
15. Campbell DJ. Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides. Braz J Med Biol Res 2000;33:665-77
16. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikrein-kininogen kinin system: lessons from the quantification of endogenous kinins. Peptides 2000;21:1903-40 (Pubitemid 32058866)
17. Scharfstein J, Schmitz V, Morandi V, et al. Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B2 receptors. J Exp Med 2000;192:1289-300
18. Passos GF, Fernandes ES, Campos MM, et al. Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J Immunol 2004;172:1839-47 (Pubitemid 38116833)
19. Maeda H, Wu J, Okamoto T, et al. Kallikrein-kinin in infection and cancer. Int Immunopharmacol 1999;43:115-28
20. Costa-Neto CM, Dillenburg-Pilla P, Heinrich TA, et al. Participation of kallikrein-kinin system in different pathologies. Int Immunopharmacol 2008;8:135-42
21. Henderson LM, Figueroa CD, Muller-Esterl W, Bhoola KD. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 1994;84:474-82 (Pubitemid 24215947)
22. Stuardo M, Gonzalez CB, Nualart F, et al. Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J Leukoc Biol 2004;4:631-40 (Pubitemid 38405654)
23. Ehrenfeld P, Millan C, Matus E, et al. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol 2006;80:117-24 (Pubitemid 44835532)
24. Ehrenfeld P, Matus CE, Pavicic F, et al. Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family. J Leukoc Biol 2009;86:1179-89
25. Slattery MJ, Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer 2003;106:713-22 (Pubitemid 36993395)
26. Tirumalai RS, Chan KC, Prieto DA, et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-103
27. Villanueva J, Shaffer DR, Philip J. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84 (Pubitemid 43121812)
28. van Winden AW, van den Broek I, Gast MC, et al. Serum degradome markers for the detection of breast cancer. J Proteome Res 2010;9:3781-8
29. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3:845-52 (Pubitemid 39405945)
30. Kang DS, Gustafsson C, Morgelin M, Leeb-Lundberg LM. B1 bradykinin receptor homo-oligomers in receptor cell surface expression and signaling: effects of receptor fragments. Mol Pharmacol 2005;67:309-18 (Pubitemid 40069992)
31. Kang DS, Ryberg K, Morgelin M, Leeb-Lundberg LM. Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced signaling capacity. J Biol Chem 2004;279:22102-7 (Pubitemid 38679402)
32. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46
33. Marceau F. Kinin B1 receptors: a review. Int Immunopharmacol 1995;30:1-26
34. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998;50:357-86
35. Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol 1999;127:1851-9 (Pubitemid 29392880)
36. Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases. Bone 2008;43:72-83
37. Guevara-Lora I, Florkowska M, Kozik A. Bradykinin-related peptides up-regulate the expression of kinin B1 and B2 receptor genes in human promonocytic cell line U937. Acta Biochim 2009;56:515-22
38. Matus CE, Ehrenfeld P, Pavicic F, et al. Activation of kinin B receptor triggers differentiation of cultured human keratinocytes. Br J Dermatol 2008;159:792-803
39. Enquist J, Skroder C, Whistler JL, Leeb-Lundberg FLM. Kinins promote B2 receptor endocytosis and delay B1 receptor endocytosis. Mol Pharmacol 2007;71:494-507 (Pubitemid 46147916)
40. Bascands JL, Pecher C, Rouaud S, et al. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol 1993;264:F548-56 (Pubitemid 23102772)
41. Smith JAM, Webb C, Holford J, Burgess GM. Signal transduction pathways for B1 and B2 bradykinin receptors in bovine pulmonary artery endothelial cells. Mol Pharmacol 1995;47:525-34
42. Mathis SA, Criscimagna NL, Leeb-Lundberg LMF. B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca2+ signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 1996;50:128-39 (Pubitemid 26250084)
43. Blaukat A, Herzer K, Schroeder C, et al. Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. Biochemistry 1999;38:1300-9
44. Clements J, Mukhtar A. Tissue kallikrein and bradykinin B2 receptor are expressed in endometrial and prostate cancer. Int Immunopharmacol 1997;36:217-20 (Pubitemid 27286324)
45. Raidoo DM, Sawant S, Mahabeer R, Bhoola KD. Kinin receptors are expressed in human astrocytic tumour cells. Int Immunopharmacol 1999;43:255-63
46. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002;98:29-35 (Pubitemid 34113414)
47. Chee J, Singh J, Naran A, et al. Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol Chem 2007;388:1235-42 (Pubitemid 350059620)
48. Matsumura Y, Kimura M, Yamamoto T, Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988;79:1327-34 (Pubitemid 20019411)
49. Matsumura Y, Maruo K, Kimura M, et al. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 1991;82:732-41
50. Toledo C, Matus CE, Barraza X, et al. Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol 2012; In press
51. Maeda H, Matsumura Y, Kato H. Purification and identification of hydroxyprolyl3BK in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988;263:16051-4 (Pubitemid 18262016)
52. Maeda H, Akaike T, Wu J, et al. Bradykinin and nitric oxide in infectious disease and cancer. Int Immunopharmacol 1996;33:222-30 (Pubitemid 26247937)
53. Barki-Harrington L, Bookout AL, Wang G, et al. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochemistry 2003;2:581-7 (Pubitemid 36547643)
54. Lu DY, Leung YM, Huang SM, Wong KL. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem 2010;110:141-50
55. Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 2011;31:4858-67
56. Vassou D, Notas G, Hatzoglou A, et al. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. Int J Oncol 2011;39:697-707
57. Hecquet C, Becker R, Tan F, Erdos EG. Kallikreins when activating bradykinin B2 receptor induce its redistribution on plasma membrane. Int Immunopharmacol 2002;2:1795-806 (Pubitemid 35373922)
58. Hecquet C, Tan F, Marcic BM, Erdos EG. Human bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 2000;58:828-36
59. Biyashev D, Tan F, Chen Z, et al. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol 2006;290:H1244-50
60. Gao L, Smith RS, Chen LM, et al. Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem 2010;39:803-12
61. Whitfield JF, MacManus JP, Gillan DJ. Cyclic AMP mediation of bradykinin-induced stimulation of mitotic activity and DNA synthesis in thymocytes. Proc Soc Exp Biol Med 1970;133:1270-4
62. Roberts RA, Gullick WJ. Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis by expression of mutant ras oncogene. J Cell Sci 1989;94:527-35 (Pubitemid 20002850)
63. Woll PJ, Rozengurt E. Multiple neuropeptides mobilise calcium in small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Res Commun 1989;164:66-73 (Pubitemid 19269696)
64. Drube S, Liebmann C. In various tumour cell lines the peptide bradykinin B2 receptor antagonist, Hoe140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 2000;131:1553-60 (Pubitemid 32056419)
65. Greco S, Elia MG, Muscella, et al. Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J Endocrinol 2005;186:291-301 (Pubitemid 41167398)
66. Greco S, Muscella A, Elia MG, et al. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 2004;201:84-96 (Pubitemid 39187047)
67. Greco S, Storelli C, Marsigliante S. Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol 2006;188:79-89 (Pubitemid 43159812)
68. Thomas SM, Bhola NE, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9 (Pubitemid 46094195)
69. Grzelinski M, Pinkenburg O, Buch T, et al. Critical role of Galpha12 and Galpha13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo. Clin Cancer Res 2010;16:1402-15
70. Bhola NE, Grandis JR. Crosstalk between G protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008;13:1857-65 (Pubitemid 351599738)
71. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 2011;331:222-31
72. Zhang W, Bhola N, Kalyankrishna S, et al. Kinin B2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res 2008;6:1946-56
73. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 2001;165:2121-5
74. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73 (Pubitemid 39129418)
75. Rehbock J, Buchinger P, Hermann A, Figueroa C. Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. J Cancer Res Clin Oncol 1995;121:64-8
76. Searovic P, Alonso M, Oses C, et al. Effect of tamoxifen and retinoic acid on bradykinin induced proliferation in MCF-7 cells. J Cell Biochem 2009;106:473-81
77. Poblete MT, Matus CE, Tapia E, et al. Breast tumours and MCF-7 cells express kinin B1 and B2 receptors. The National Cancer Research Institute Cancer Conference; Birmingham, UK; 2006. p. 170-Available from: http://www.ncri.org. uk/ncriconference/archive/2006/abstracts/pdf/NCRI2006-0280.pdf Last accessed 1 February 2012
78. Esseghir S, Reis-Filho JS, Kennedy A, et al. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 2006;210:420-30 (Pubitemid 44830602)
79. Morissette G, Houle S, Gera L, et al. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol 2007;150:369-79 (Pubitemid 46221045)
80. Ehrenfeld P, Figueroa CD, Bhoola KD. Kinins: kallikreins and kinins in cancer. In: Bader M, editor. Kinins. Walter de Gruyter GmbH y Co. KG; Berlin/New York: 2011. p. 217-45
81. Stewart JM, Vavrek RJ. Bradykinin chemistry: agonists and antagonists. Adv Exp Med Biol 1983;156:585-9
82. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985;6:161-4 (Pubitemid 15051811)
83. Stewart JM, Vavrek RJ. Bradykinin competitive antagonists for classical kinin systems. Adv Exp Med Biol 1986;198(Pt A):537-42
84. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-73
85. Kyle DJ, Martin JA, Farmer SG, Burch RM. Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem 1991;34:1230-3
86. Miskolzie M, Gera L, Stewart JM, Kotovych G. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity. J Biomol Struct Dyn 2002;19:585-93 (Pubitemid 34242138)
87. Cheronis JC, Whalley ET, Allen LG, et al. Design, synthesis, and in vitro activity of bis(succinimido)hexane peptide heterodimers with combined B1 and B2 antagonist activity. J Med Chem 1994;37:348-55 (Pubitemid 24079944)
88. Cheronis JC, Whalley ET, Nguyen KT, et al. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem1992;35:1563-72
89. Chan D, Gera L, Helfrich B, et al. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Int Immunopharmacol 1996;33:201-4 (Pubitemid 26247933)
90. Chan D, Gera L, Stewart J, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci USA 2002a;99:4608-13 (Pubitemid 34286032)
91. Chan DC, Gera L, Stewart JM, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 2002b;8:1280-7 (Pubitemid 34517669)
92. Chee J, Naran A, Misso NL, et al. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 2008;389:1225-33
93. Gera L, Stewart JM, Whalley E, et al. A new class of potent bradykinin antagonist dimers. Int Immunopharmacol 1996;33:178-82 (Pubitemid 26247927)
94. Stewart JM, Gera L, Chan DC, et al. Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 2002;80:275-80 (Pubitemid 34451242)
95. Stewart JM, Gera L. Bradykinin and cancer. Handbook of Biologically Active Peptides. Elsevier; Amsterdam: 2006. p. 443-6
96. Stewart JM, Gera L, Chan DC, et al. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 2005;26:1288-91 (Pubitemid 41021461)
97. Jutras S, Bachvarova M, Keita M, et al. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells-analysis of the molecular mechanism of its antiproliferative action. FEBS J 2010;277:5146-60
98. Emanueli C, Madeddu P. Effect of early blockade of bradykinin B2-receptors on the blood pressure phenotype of normotensive and spontaneously hypertensive rats. Pharmacol Res 1997;35:522-6
99. Madeddu P, Varoni MV, Palomba D, et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997;96:3570-8 (Pubitemid 27513435)
100. Bunn PA Jr, Chan D, Dienhart DG, et al. Neuropeptide signal transduction in lung cancer: clinical implications of Bradykinin sensitivity and overall heterogeneity. Cancer Res 1992;52:24-31
101. Meacci E, Nuti F, Catarzi S, et al. Activation of phospholipase D by bradykinin and sphingosine 1-phosphate in A549 human lung adenocarcinoma cells via different GTP-binding proteins and protein kinase C delta signaling pathways. Biochemistry 2003;42:284-92 (Pubitemid 36105746)
102. Wong J, Sia YY, Misso NL, et al. Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura. Pathol Res Int 2011;167046:published online 4 September 2011; doi:10.4061/2011/167046
103. Motadi LR, Misso N, Dlamini Z, Bhoola KD. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets. Int Immunopharmacol 2007;7:1934-47 (Pubitemid 350138515)
104. Bhoola KD, Ng A, Wong J, et al. Expression and epigenetic regulation of kallikreins and kinin receptors in pleural mesothelioma cells. Respirology 2009;14(Suppl 1):A65
105. Dlamini Z, Raidoo D, Bhoola K. Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Int Immunopharmacol 1999;43:303-10
106. Dlamini Z, Bhoola KD. Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 2005;58:915-22 (Pubitemid 41265274)
107. Zelawski W, Machnik G, Nowaczyk G, et al. Expression and localisation of kinin receptors in colorectal polyps. Int Immunopharmacol 2006;6:997-1002
108. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome cancer biomarkers. Clin Proteomics 2010;6:115-27
109. Cuschieri A. Activation of the kinin-forming system during therapy with cyclophosphamide. Clin Chem 1974;20:19-21
110. Zhao Y, Xue Y, Liu Y, et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br J Neurosurg 2005;19:322-6 (Pubitemid 43220790)
111. Wang YB, Peng C, Liu YH. Low dose of bradykinin selectively increases intracellular calcium in glioma cells. J Neurol Sci 2007;258:44-51 (Pubitemid 46874476)
112. Wang YB, Liu YH. Bradykinin selectively modulates the blood-tumor barrier via calcium-induced calcium release. J Neurosci Res 2009;87:660-7
113. Liu LB, Xue YX, Liu YH, Wang YB. Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J Neurosci Res 2008;86:1153-68
114. Fujita M, Andoh T, Ohashi K, et al. Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur J Pain 2009;14:588-94
115. Andoh T, Akira A, Saik I, Kuraishi Y. Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides 2010;31:238-41
116. Yang WH, Chang JT, Hsu SF, et al. Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J Cell Biochem 2010;109:82-92
117. Moodley R, Snyman C, Odhav B, Bhoola KD. Visualisation of transforming growth factor-beta1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Biol Chem 2005;386:375-82 (Pubitemid 41447600)